Tysabri Information Center
Recent News
- Data Supporting Unique Efficacy of TYSABRI Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (9/11/09)
- MRI Data Showing TYSABRI® Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology (4/28/09)
- MS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology (2/9/09)
- Form 6-K (12/15/08)
- Form 6-K (10/30/08
- Form 6-K (7/31/2008)
- Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI® for the Treatment of Multiple Sclerosis (7/22/08)
- Data Presented at the 60th Annual Meeting of the American Academy of Neurology Offers Additional Support for Plasma Exchange as a Potential Tool to Accelerate TYSABRI® Removal (4/16/08)
- Biogen Idec and Elan Present New TYSABRI® Data at the 60th Annual Meeting of the American Academy of Neurology (4/15/08)
- FDA Approves TYSABRI® for the Treatment of Moderate-to-Severe Crohn's Disease (1/14/08)
- Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI® in Patients with Multiple Sclerosis (1/7/08)